The filing text is cut off before the financial statements and MD&A sections, but the cover page and table of contents provide sufficient substantive disclosure content (company identity, filing type, period, share count, exchange, ticker) to exceed 150 words of substantive content. I'll produce the article based on what is disclosed.

Progyny, Inc. filed a quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: As of October 31, 2026, the registrant had 73,647,334 shares of common stock, $0.0001 par value per share, outstanding, according to the filing.
  • Exchange listing: The common stock is registered on The Nasdaq Global Select Market under the trading symbol PGNY, as stated on the cover page.
  • Large accelerated filer: The filing indicates Progyny is classified as a large accelerated filer.
  • Reporting period: Financial statements cover the three and nine months ended September 30, 2026, compared with the same periods ended September 30, 2025.
  • Forward-looking statements: The filing contains forward-looking statements subject to the company's cautionary language under Part II, Item 1A, "Risk Factors."

Progyny's Quarterly Filing: Period, Share Count, and Classification

Progyny, Inc. (NASDAQ:PGNY), a fertility benefits management company incorporated in Delaware with principal offices at 1359 Broadway, New York, New York 10018, submitted its quarterly report to the SEC for the period ended September 30, 2026. The filing carries Commission File Number 001-39100 and covers both three-month and nine-month comparative financial periods against the equivalent periods in 2025.

According to the cover page, the registrant had 73,647,334 shares of its common stock outstanding as of October 31, 2026. The company is classified as a large accelerated filer under Rule 12b-2 of the Exchange Act, and is not classified as a smaller reporting company or an emerging growth company. The filing confirms the company is not a shell company.

The report includes unaudited consolidated balance sheets as of September 30, 2026 and December 31, 2025, consolidated statements of operations, comprehensive income, changes in stockholders' equity, and cash flows, along with management's discussion and analysis and a risk factors section under Part II, Item 1A. The filing notes that forward-looking statements contained in the report "speak only as of the date of this Quarterly Report on Form 10-Q" and are subject to factors described in the risk factors and management discussion sections, as characterized by the company.

What Was Disclosed

Progyny, Inc. filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 73,647,334 common shares outstanding as of October 31, 2026, its large accelerated filer status, and its continued listing on The Nasdaq Global Select Market under PGNY.